IQVIA (NYSE:IQV) Announces Quarterly Earnings Results

IQVIA (NYSE:IQV) announced its quarterly earnings results on Tuesday. The medical research company reported $3.15 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $3.03 by $0.12, FiscalAI reports. The business had revenue of $4.37 billion during the quarter, compared to the consensus estimate of $4.30 billion. IQVIA had a net margin of 8.33% and a return on equity of 30.50%. The business’s revenue was up 8.7% compared to the same quarter last year. During the same quarter last year, the firm earned $2.81 EPS. IQVIA updated its FY 2026 guidance to 12.800-13.000 EPS.

IQVIA Stock Up 15.1%

Shares of NYSE:IQV opened at $245.40 on Tuesday. The company has a debt-to-equity ratio of 2.20, a current ratio of 0.75 and a quick ratio of 0.75. The stock has a market cap of $40.96 billion, a P/E ratio of 30.20, a P/E/G ratio of 1.87 and a beta of 1.20. IQVIA has a 1-year low of $154.50 and a 1-year high of $247.04. The firm has a fifty day moving average price of $189.02 and a 200 day moving average price of $186.85.

Analyst Upgrades and Downgrades

A number of equities research analysts have commented on the company. Morgan Stanley restated an “equal weight” rating and issued a $200.00 target price (down from $225.00) on shares of IQVIA in a research report on Wednesday, June 17th. Mizuho lifted their price target on shares of IQVIA from $215.00 to $230.00 and gave the company an “outperform” rating in a research report on Monday, July 13th. HSBC reaffirmed a “buy” rating and set a $240.00 price objective on shares of IQVIA in a research report on Monday, July 6th. Wall Street Zen lowered IQVIA from a “buy” rating to a “hold” rating in a research report on Saturday, June 27th. Finally, Weiss Ratings raised IQVIA from a “hold (c-)” rating to a “hold (c)” rating in a research note on Wednesday, July 15th. Thirteen equities research analysts have rated the stock with a Buy rating and three have assigned a Hold rating to the company’s stock. Based on data from MarketBeat.com, IQVIA presently has an average rating of “Moderate Buy” and a consensus price target of $225.71.

IQVIA announced that its board has approved a stock repurchase plan on Thursday, May 7th that allows the company to repurchase $2.00 billion in shares. This repurchase authorization allows the medical research company to reacquire up to 6.8% of its stock through open market purchases. Stock repurchase plans are generally an indication that the company’s board of directors believes its shares are undervalued.

Institutional Trading of IQVIA

Several institutional investors and hedge funds have recently added to or reduced their stakes in the stock. Gilpin Wealth Management LLC acquired a new position in shares of IQVIA in the fourth quarter valued at approximately $27,000. CrossGen Wealth LLC acquired a new position in IQVIA in the 4th quarter valued at $28,000. Measured Wealth Private Client Group LLC purchased a new stake in shares of IQVIA in the third quarter valued at about $30,000. Johnson Financial Group Inc. purchased a new position in IQVIA during the third quarter worth about $52,000. Finally, DV Equities LLC purchased a new stake in IQVIA in the 4th quarter valued at approximately $53,000. 89.62% of the stock is owned by hedge funds and other institutional investors.

IQVIA Company Profile

IQVIA (NYSE: IQV) is a global provider of advanced analytics, technology solutions and contract research services to the life sciences industry. The company combines clinical research capabilities with large-scale health data and analytics to support drug development, regulatory reporting, commercial strategy and real‑world evidence generation. IQVIA traces its current form to the combination of Quintiles and IMS Health announced in 2016 and subsequently rebranded as IQVIA, bringing together long-established clinical research operations and extensive healthcare information assets.

IQVIA’s principal activities include outsourced clinical development services (acting as a contract research organization for phases I–IV), real‑world evidence and observational research, regulatory and safety services, and a suite of technology platforms that enable data integration, analytics and operational management.